Published in HIV AIDS (Auckl) on April 28, 2011
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog (2015) 1.61
Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review. J Int AIDS Soc (2015) 0.90
Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz. Pediatric Health Med Ther (2014) 0.79
Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. HIV AIDS (Auckl) (2012) 0.77
Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland. J Int AIDS Soc (2014) 0.77
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem (2005) 2.31
Examining the production costs of antiretroviral drugs. AIDS (2006) 1.97
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm (2009) 1.70
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS (2010) 1.41
Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother (2010) 1.35
Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects. AIDS (2006) 1.23
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS (2010) 1.15
Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother (2009) 1.09
Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis (2010) 1.05
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother (2009) 1.01
Ethical allocation of preexposure HIV prophylaxis. JAMA (2011) 0.99
Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs (2009) 0.97
Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir Ther (2009) 0.90
Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies. Eur J Pharm Biopharm (2008) 0.85
Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs Today (Barc) (2011) 0.83
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (2010) 4.41
Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. J Acquir Immune Defic Syndr (2013) 3.02
Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS (2008) 2.85
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis (2009) 2.78
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS (2010) 2.49
Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA (2010) 2.12
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis (2012) 2.04
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis (2004) 1.89
Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc (2011) 1.88
The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS (2015) 1.84
Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières. AIDS (2003) 1.69
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis (2013) 1.68
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS (2014) 1.67
Reduction of missed appointments at an urban primary care clinic: a randomised controlled study. BMC Fam Pract (2010) 1.62
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS (2007) 1.49
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS (2013) 1.49
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol (2013) 1.48
Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. AIDS (2004) 1.48
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics (2010) 1.46
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS (2012) 1.42
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS (2010) 1.41
Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. AIDS (2015) 1.41
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS (2011) 1.40
Expert reviews: who are they for? Expert Opin Pharmacother (2012) 1.39
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther (2010) 1.30
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther (2005) 1.30
The first decade of antiretroviral therapy in Africa. Global Health (2011) 1.27
Patient needs and point-of-care requirements for HIV load testing in resource-limited settings. J Infect Dis (2010) 1.23
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses (2008) 1.19
Public health. Getting HIV treatment to the most people. Science (2012) 1.19
Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. PLoS One (2011) 1.15
Relative roles of the cellular and humoral responses in the Drosophila host defense against three gram-positive bacterial infections. PLoS One (2011) 1.14
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. Drug Discov Today (2008) 1.14
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon. J Acquir Immune Defic Syndr (2008) 1.14
Pseudomonas aeruginosa RhlR is required to neutralize the cellular immune response in a Drosophila melanogaster oral infection model. Proc Natl Acad Sci U S A (2011) 1.13
Viral load monitoring in resource-limited settings: a medical and public health priority. AIDS (2012) 1.13
Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS (2010) 1.13
Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol (2011) 1.10
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 1.09
Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr (2011) 1.09
Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings. J Antimicrob Chemother (2009) 1.08
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS (2008) 1.08
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia. Clin Infect Dis (2014) 1.07
HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis. PLoS Genet (2013) 1.04
Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother (2011) 1.04
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther (2009) 1.03
Rationing antiretroviral therapy in Africa--treating too few, too late. N Engl J Med (2009) 1.02
Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS (2007) 1.01
Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. AIDS (2012) 1.00
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 0.98
Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis (2013) 0.97
Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis (2011) 0.97
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis (2013) 0.96
Effects of arsenic on human keratinocytes: morphological, physiological, and precursor incorporation studies. Environ Res (2002) 0.96
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. AIDS (2015) 0.95
Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health (2014) 0.95
Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. PLoS One (2013) 0.95
HIV treatment for prevention. J Int AIDS Soc (2011) 0.93
Cross-sectional human mandibular morphology as assessed in vivo by cone-beam computed tomography in patients with different vertical facial dimensions. Am J Orthod Dentofacial Orthop (2011) 0.93
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. J Mass Spectrom (2013) 0.92
Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals. World J Gastroenterol (2011) 0.92
A randomized crossover study to compare efavirenz and etravirine treatment. AIDS (2011) 0.91
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2012) 0.91
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS (2011) 0.90
Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. J Acquir Immune Defic Syndr (2015) 0.90
Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis. AIDS Behav (2012) 0.89
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health (2010) 0.89
Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS (2013) 0.89
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother (2010) 0.89
Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2015) 0.87
Musculoskeletal differentiation of cells derived from human embryonic germ cells. Stem Cells (2005) 0.87
Hit me with your best shot: dolutegravir - a space in the next WHO guidelines? AIDS (2015) 0.87
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PLoS One (2012) 0.86
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenet Genomics (2013) 0.85
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PLoS One (2012) 0.85
Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. J Infect Dis (2014) 0.85
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia. AIDS (2012) 0.84
Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. AIDS (2015) 0.84
Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother (2014) 0.83
Successful efavirenz dose reduction guided by therapeutic drug monitoring. Antivir Ther (2011) 0.83
Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS (2014) 0.83
When to start antiretroviral therapy in resource-limited settings: a human rights analysis. BMC Int Health Hum Rights (2010) 0.83
Health perceptions of African HIV-infected patients and their physicians. Patient Educ Couns (2009) 0.82
Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRI. Dermatology (2015) 0.81
Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field. PLoS One (2013) 0.81
Treating HIV in the developing world: getting ahead of the drug development curve. Drug Discov Today (2006) 0.80
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study. Neurology (2013) 0.80
HIV drug resistance. N Engl J Med (2004) 0.80
Preferred antiretroviral drugs for the next decade of scale up. J Int AIDS Soc (2012) 0.80
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS (2004) 0.79